After Abeta Blow, Biogen And Eisai Get BACE Boost

Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.

Caution
BACE inhibitors have not fared well in the clinic

Eisai Co. Ltd. and Biogen Inc. should continue with their Phase III trial of elenbecestat in early Alzheimer’s disease, according to the data safety and monitoring board for the program. The DSMB recommendation came after a review of safety data, including the potential for decline in cognition.

The news will be a relief for the partners, which on March 21, 2019 announced the discontinuation of their most...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category